Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria

Cindy S Chu, Aung Pyae Phyo, Claudia Turner, Htun Htun Win, Naw Pet Poe, Widi Yotyingaphiram, Suradet Thinraow, Pornpimon Wilairisak, Rattanaporn Raksapraidee, Verena I Carrara, Moo Kho Paw, Jacher Wiladphaingern, Stéphane Proux, Germana Bancone, Kanlaya Sriprawat, Sue J Lee, Atthanee Jeeyapant, James Watson, Joel Tarning, Mallika Imwong, François Nosten, Nicholas J White, Cindy S Chu, Aung Pyae Phyo, Claudia Turner, Htun Htun Win, Naw Pet Poe, Widi Yotyingaphiram, Suradet Thinraow, Pornpimon Wilairisak, Rattanaporn Raksapraidee, Verena I Carrara, Moo Kho Paw, Jacher Wiladphaingern, Stéphane Proux, Germana Bancone, Kanlaya Sriprawat, Sue J Lee, Atthanee Jeeyapant, James Watson, Joel Tarning, Mallika Imwong, François Nosten, Nicholas J White

Abstract

Background: Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertain. A randomized controlled trial was performed to compare the tolerability and radical curative efficacy of 7-day versus 14-day high-dose primaquine regimens (total dose 7mg/kg) with either chloroquine or dihydroartemisinin-piperaquine.

Methods: Patients with uncomplicated P. vivax malaria on the Thailand-Myanmar border were randomized to either chloroquine (25mg base/kg) or dihydroartemisinin-piperaquine (dihydroartemisinin 7mg/kg and piperaquine 55mg/kg) plus primaquine, either 0.5 mg/kg/day for 14 days or 1 mg/kg/day for 7 days. Adverse events within 42 days and 1-year recurrence rates were compared and their relationship with day 6 drug concentrations assessed.

Results: Between February 2012 and July 2014, 680 patients were enrolled. P. vivax recurrences (all after day 35) occurred in 80/654 (12%) patients; there was no difference between treatments. Compared to the 7-day primaquine groups the pooled relative risk of recurrence in the 14-day groups was 1.15 (95% confidence interval 0.7 to 1.8). Hematocrit reductions were clinically insignificant except in G6PD female heterozygotes, 2 of whom had hematocrit reductions to <23% requiring blood transfusion.

Conclusion: Radical cure should be deployed more widely. The radical curative efficacy in vivax malaria of 7-day high-dose primaquine is similar to the standard 14-day high-dose regimen. Chloroquine and dihydroartemisinin-piperaquine are both highly effective treatments of the blood stage infection. Quantitative point of care G6PD testing would ensure safe use of the 7-day high-dose primaquine regimen in G6PD heterozygous females.

Clinical trials registration: NCT01640574.

Keywords: Plasmodium vivax; chloroquine; dihydroartemisinin-piperaquine; primaquine; radical cure.

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Study diagram. aOne patient randomized to the CP7 arm was given DP7 bTwo patients randomized to the CP14 arm were given CP7 cTwo patients vomited the drug treatment twice and one patient had received a blood transfusion in the prior 3 months. dA total of 26 patient were excluded from the analyses because they had not completed the schizonticidal treatment. The three patients with incorrect randomization were included in the analysis. Abbreviations: CP7, Chloroquine + Primaquine 1 mg/kg/day for 7 days; CP14, Chloroquine + Primaquine 0.5 mg/kg/day for 14 days; DP7, Dihydroartemisinin-piperaquine + Primaquine 1 mg/kg/day for 7 days; DP14, Dihydroartemisinin-piperaquine + Primaquine 0.5 mg/kg/day for 14 days; G6PD, glucose-6-phosphate dehydrogenase.
Figure 2.
Figure 2.
Recurrence of Plasmodium vivax malaria during the 1-year study. Survival curves comparing marginal time to first recurrence in the 2 schizontocide groups (left panel) and the 2 radical cure groups (right panel). Vertical notches denote right censored observations. 95% confidence intervals are shown by the shaded areas. The dashed black line shows the proportion recurring when not given radical cure in recent (two years previous) historical controls from the same study site [22].
Figure 3.
Figure 3.
Noninferiority analysis of the 7-day versus 14-day high-dose primaquine regimens. The relative risk of a new Plasmodium vivax infection in the 7-day high-dose primaquine regimen (13.5%) was not inferior to the 14-day regimen (15.3%). The difference in relative risk between the two regimens was 1.8% (95% confidence interval −9.8 to +6.7%).
Figure 4.
Figure 4.
Risk of Plasmodium vivax relapse in relation to primaquine and carboxyprimaquine drug levels. The predicted individual risks of recurrence within 1 year as a function of day 7 primaquine (left panel) and carboxy-primaquine (right panel) concentrations. These relationships are estimated from a mixed effects Cox proportional hazards model where sex, schizonticide treatment, and primaquine and carboxy-primaquine concentrations were independent predictive covariates.
Figure 5.
Figure 5.
Median methemoglobin measurements during primaquine administration. Evolution of methemoglobin concentrations over time within the four study groups. Data from PMQ7 arm are shown in light and dark red for CQ and DP, respectively. Data from PMQ14 are shown in light and dark blue for CQ and DP, respectively. The thick brown and aqua lines correspond to the median trends for the pooled 7-day and 14-day primaquine groups, respectively. Abbreviations: CQ, chloroquine; DP, dihydroartemisinin-piperaquine, PMQ7, primaquine 1 mg/kg/day for 7 days; PMQ14, primaquine 0.5 mg/kg/day for 14 days.

References

    1. Battle KE, Gething PW, Elyazar IRF, et al. . The global public health significance of Plasmodium vivax. Adv Parisitol 2012; 80:1–111.
    1. World Health Organization. Guidelines for the treatment of malaria, 3rd ed. Geneva: World Health Organization.
    1. Commons RJ, Thriemer K, Humphreys G, et al. . The vivax surveyor: online mapping database for Plasmodium vivax clinical trials. Int J Parasitol Drugs Drug Resist 2017; 7:181–90.
    1. Phyo AP, Lwin KM, Price RN, et al. . Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis 2011; 53:977–84.
    1. Betuela I, Rosanas-Urgell A, Kiniboro B, et al. . Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1–5 years of age. J Infect Dis 2012; 206:1771–80.
    1. Nelwan EJ, Ekawati LL, Tjahjono B, et al. . Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. BMC Med 2015; 13:294.
    1. Khantikul N, Butraporn P, Kim HS, Leemingsawat S, Tempongko MA, Suwonkerd W. Adherence to antimalarial drug therapy among vivax malaria patients in Northern Thailand. J Health Popul Nutr 2009; 27:4–13.
    1. Takeuchi R, Lawpoolsri S, Imwong M, et al. . Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. Malar J 2010; 9:308.
    1. Grietens KP, Soto V, Erhart A, et al. . Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon. Am J Trop Med Hyg 2010; 82:1017–23.
    1. Maneeboonyang W, Lawpoolsri S, Puangsa-Art S, et al. . Directly observed therapy with primaquine to reduce the recurrence rate of Plasmodium vivax infection along the Thai-Myanmar border. SouthEast Asian J Trop Med Public Health 2011; 42:9–18.
    1. Roy RG, Chakrapani KP, Dhinagaran D, Sitaraman NL, Ghosh RB. Efficacy of 5-day radical treatment of P. vivax infection in Tamil Nadu. Indian J Med Res 1977; 65:652–6.
    1. Gogtay N, Garg M, Kadam V, Kamtekar K, Kshirsagar NA. A 5 days primaquine regimen as anti-relapse therapy for Plasmodium vivax. Trans R Soc Trop Med Hyg 1998; 92:341.
    1. Contacos PG, Coatney GR, Collins WE, Briesch PE, Jeter MH. Five day primaquine therapy: an evaluation of radical curative activity against vivax malaria infection. Am J Trop Med Hyg 1973; 22:693–5.
    1. Gogtay NJ, Desai S, Kamtekar KD, Kadam VS, Dalvi SS, Kshirsagar NA. Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections. Ann Trop Med Parasitol 1999; 93:809–12.
    1. Clyde DF, McCarthy VC. Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. Am J Trop Med Hyg 1977; 26:562–3.
    1. Pukrittayakamee S, Imwong M, Chotivanich K, Singhasivanon P, Day NP, White NJ. A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. Am J Trop Med Hyg 2010; 82:542–7.
    1. Carrara VI, Lwin KM, Phyo AP, et al. . Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai–Myanmar border, 1999–2011: an observational study. PLoS Med 2013;10:e1001398.
    1. Beutler E, Mitchell M. Special modifications of the fluorescent screening method for glucose-6-phosphate dehydrogenase deficiency. Blood 1968; 32:816–8.
    1. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ; CONSORT Group Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006; 295:1152–60.
    1. Schumi J, Wittes JT. Through the looking glass: understanding non-inferiority. Trials 2011; 12:106.
    1. Chu CS, Bancone G, Moore KA, et al. . Haemolysis in G6PD heterozygous females treated with primaquine for Plasmodium vivax Malaria: a nested cohort in a trial of radical curative regimens. PLoS Med 2017; 14:e1002224.
    1. Chu CS, Phyo AP, Lwin KM, et al. . Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in Plasmodium vivax malaria. Clin Infect Dis 2018:1–7.
    1. Baird JK, Wiady I, Fryauff DJ, et al. . In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. Am J Trop Med Hyg 1997; 56:627–31.
    1. Price RN, Hasugian AR, Ratcliff A, et al. . Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother 2007; 51:4090–7.
    1. Krudsood S, Tangpukdee N, Wilairatana P, et al. . High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am J Trop Med Hyg 2008; 78:736–40.
    1. Ebringer A, Heathcote G, Baker J, Waller M, Shanks GD, Edstein MD. Evaluation of the safety and tolerability of a short higher-dose primaquine regimen for presumptive anti-relapse therapy in healthy subjects. Trans R Soc Trop Med Hyg 2011; 105:568–73.
    1. Luxemburger C, van Vugt M, Jonathan S, et al. . Treatment of vivax malaria on the Western border of Thailand. Trans R Soc Trop Med Hyg 1999; 93:433–8.
    1. Pukrittayakamee S, Imwong M, Looareesuwan S, White NJ. Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Trop 2004; 89:351–6.
    1. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, et al. . Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 2014; 383:1049–58.
    1. Improving the radical cure of vivax malaria: a multicentre randomised comparison of short and long course primaquine regimens [Internet] Available at:
    1. Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White NJ. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 1994; 169:932–5.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit